Enicepatide (CT-388)

InvestigationalMetabolic ResearchWeight & metabolic

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is Enicepatide (CT-388)?

Roche describes enicepatide, formerly CT-388, as an investigational GLP-1 and GIP dual receptor agonist. Phase 3 studies are now registered and recruiting, and there is no FDA-approved enicepatide product.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for Enicepatide (CT-388) yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalInvestigational
CompoundingNo FDA-approved product; compounding eligibility is not established

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.